QuantuMDx wins MediLink Award 2022

NEWCASTLE UPON TYNE, UK, [13] May 2022. QuantuMDx Group Limited (“QuantuMDx”), is pleased to announce that it has won the Innovation Award at the Medilink Healthcare Business Awards 2022.

The Innovation Award was awarded to the Company’s Q-POC™ platform, recognising the pioneering technology and design that has been developed and its potential to meet a serious unmet need as it provides accurate, high quality PCR results at the point of need in clinical and non-clinical settings.

The award is the latest to be awarded to the Q-POC™ platform, highlighting the innovation of the device and the achievements of the QuantuMDx team in developing the product and successfully bringing the platform to market.

QuantuMDx would like to congratulate the whole team on this achievement. The team continues to work hard on the development of the Company’s future R&D projects, including a multiplex respiratory panel, which is due to be launched soon.

Jonathan O’Halloran, Chief Executive Officer, QuantuMDx, said: “This award further validates our innovative technology and are a credit to our hard-working team. We are continuing to build on the momentum of the last year, during which we were pleased to receive CDTA approval of our Q-POC™ SARS-CoV-2 assay and the Company is now working to expand the menu of tests for Q-POC™ and further develop our technology. We will soon be launching our next assay, a SARS-CoV-2, Flu A/B & RSV panel, which will provide a differential diagnosis to enable rapid triage and patient stratification into the appropriate treatment strategy, in approximately 30 minutes at the point of need. We remain committed to providing accurate and affordable testing for healthcare professionals and are looking forward to providing further updates on our innovative product range in due course.”

Notes to editor:

About QuantuMDx

QuantuMDx is a progressive MedTech company passionate about empowering the world to control disease and reduce suffering. QuantuMDx solves real-world diagnostic problems by creating multiplex molecular solutions for the Point of Need, for anyone, anywhere.

QuantuMDx has global operations and strategic partnerships – keeping it at the forefront of molecular diagnostics. 

Q-POC™ is a rapid, simple to use, portable, sample to answer multiplex PCR device. It has been designed for use in a range of real-world settings, such as hospitals, clinics, pharmacies, dentistry, workplaces and in the field, providing accurate PCR results at the Point of Need. 

Q-POC™ and its first test, a SARS-CoV-2 multiplex detection assay, are CE-IVD marked under the In Vitro Diagnostics Directive (98/79/EC), enabling use within Europe. It tests multiple targets of the disease for a future proof Covid testing solution at the Point of Need.

QuantuMDx plans to launch a range of syndromic multiplex testing assays over the coming months and years. 

For more information about QuantuMDx and Q-POC™, its rapid PCR point of care system, go to: www.quantumdx.com

For media enquiries and interview requests:

Emma Long, Marketing Communications Manager, QuantuMDx, M: +44 (0) 7495 341 930  T: +44 (0) 870 803 1234  E: emma.long@quantumdx.com

Chris Gardner, Matthew Neal and Lindsey Neville, Consilium Strategic Communications, +44 (0)20 3709 5700 / quantumdx@consilium-comms.com

For investor enquiries:

David Wilson, Nigel Barnes and Jeff Glushakow, WG Partners (Financial Adviser to QuantuMDx), +44 (0)20 3705 9330 / quantumdx@wgpartners.co.uk